Neuralstem, Inc. — Form 10-K Summary
Filing-period note: The provided filing is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the fiscal year ended December 31, 2012, rather than a standalone 2012 fourth quarter.
Business Context and Reporting Period
Neuralstem is a development-stage biopharmaceutical company focused on human neural stem-cell therapies and small-molecule compounds for central nervous system diseases. Its principal programs included NSI-566 for ALS, chronic spinal cord injury, and ischemic stroke, and NSI-189 for major depressive disorder. No product candidates had reached commercialization.
- ALS NSI-566 Phase I trial completed with 18 patients treated; Phase II was anticipated in the first half of 2013.
- FDA approval for a Phase I chronic spinal cord injury trial was announced in January 2013.
- A China-based combined Phase I/II ischemic stroke trial was expected to begin in the first quarter of 2013.
- NSI-189 Phase Ib treatment had begun, with two of three cohorts dosed.
- The company owned or exclusively licensed 30 issued patents and 42 patent applications.
Financial Performance and Position
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $407,708 | $390,625 | Approximately 4% increase |
| Operating expenses | $10,564,164 | $13,381,095 | 21% decrease |
| Operating loss | $10,156,456 | $12,990,470 | Improved by approximately $2.8 million |
| Net loss | $10,121,517 | $12,518,527 | Improved by approximately $2.4 million |
| Basic and diluted loss per share | $0.17 loss | $0.26 loss | Improved |
| Cash used in operating activities | $8,477,700 | $8,096,696 | 5% increase in use |
| Cash and cash equivalents | $7,443,773 | $2,352,013 | 216% increase |
| Cash provided by financing activities | $13,824,318 | $1,668,326 | Material increase |
Revenue consisted primarily of $234,000 from a Department of Defense subcontract and approximately $173,000 from intellectual-property licensing. The company reported no revenue from product sales. Research and development expense was $6.1 million, while general and administrative expense was $4.2 million. The filing does not provide a clear gross margin because the reported revenue was primarily contract and licensing revenue and no cost-of-revenue figure is presented.
Working capital surplus was approximately $5.9 million and stockholders’ equity was approximately $7.0 million at December 31, 2012. Total liabilities were approximately $1.8 million, consisting primarily of current payables, accrued expenses, bonuses, and other current liabilities. The filing does not identify material long-term debt; a $65,090 note-payable repayment was reported during 2012.
Material Changes Versus 2011
- Operating expenses declined 21%, principally because of lower stock-based compensation, reduced legal expenses, and lower employee salary and bonus costs.
- Research and development expense declined 17% to approximately $6.1 million, partly because certain studies were completed in 2011.
- General and administrative expense declined 27% to approximately $4.2 million, including a roughly $797,000 reduction in legal expenses related to patent litigation.
- Cash increased by approximately $5.1 million, driven by approximately $13.7 million of net proceeds from stock and warrant offerings, partly offset by operating cash use.
- Shares outstanding increased to 68.2 million at year-end from 48.7 million, reflecting substantial equity financing and related dilution.
- The Department of Defense subcontract was completed in the second quarter of 2012, and no extension options had been exercised as of the filing.
- Other income declined substantially because 2011 included a $250,000 litigation settlement and a $161,809 gain from warrant-liability valuation changes.
Outlook, Risks, Contingencies, and Unusual Items
Management expected continued operating losses and stated that the company did not expect to become profitable in the next several years. Monthly operating cash burn was approximately $780,000. Management believed available cash, expected income, and anticipated securities proceeds could fund current activities through at least December 31, 2013, although reductions in activities and personnel could be required.
- Additional financing was expected to be necessary to fund clinical trials, regulatory work, manufacturing, and operations. Approximately $28.9 million remained available under an effective shelf registration statement.
- All product candidates remained subject to substantial clinical, manufacturing, regulatory, reimbursement, and market-acceptance risks. Early-stage results were not predictive of later-stage success.
- Manufacturing and clinical-trial activities depended heavily on third-party contract manufacturers, research organizations, investigators, and laboratories.
- The company faced ongoing patent litigation with StemCells, Inc.; the proceedings were stayed while standing-related discovery continued, and the outcome and timing of resolution were uncertain.
- Employment agreements with the chief executive officer and chief scientific officer ran through October 31, 2017 and could create significant termination obligations, including accelerated vesting of equity awards.
- The company had approximately $108.6 million of accumulated losses and approximately $71.4 million of federal net operating loss carryforwards, subject to limitations on future use.
- The company reported no cash dividends and expected none in the foreseeable future.
Investor Verification Checklist
- Confirm the issuer identity: the source filing is Neuralstem, Inc., while the request metadata identifies Palisade Bio, Inc.
- Verify that the intended period is the full fiscal year ended December 31, 2012, not fourth-quarter results.
- Review the audited financial statements for cash runway, operating cash burn, equity financing terms, and dilution from options and warrants.
- Track clinical-trial commencement, enrollment, safety, efficacy, and regulatory updates for NSI-566 and NSI-189.
- Assess the need, timing, and terms of future financing and the potential effect of additional securities issuance.
- Review the status and potential financial impact of the StemCells patent litigation and other intellectual-property claims.